SRRK | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 12%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.14%

1 Month

-3.09%

3 Months

1.99%

6 Months

46.14%

1 Year

27.73%

2 Year

181.75%

Key data

Stock price

$46.15

P/E Ratio

0.00

DAY RANGE

$45.23 - $48.15

EPS

-$3.17

52 WEEK RANGE

$22.71 - $49.82

52 WEEK CHANGE

$28.19

MARKET CAP

3.580 B

YIELD

N/A

SHARES OUTSTANDING

102.007 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

3.33

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,560,886

AVERAGE 30 VOLUME

$1,161,199

Company detail

CEO: Jay T. Backstrom
Region: US
Website: scholarrock.com
Employees: 140
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Scholar Rock Holding Corporation focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin, and SRK-181, which is in Phase 1 clinical trials. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients.

SRRK - Scholar Rock Holding Corp